Sparrow Pharmaceuticals

About:

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.

Website: https://sparrowpharma.com

Twitter/X: sparrowpharma

Top Investors: OrbiMed, U.S. Venture Partners, RiverVest

Description:

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess. It was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, a novel treatment designed to target the source of active intracellular corticosteroids in key tissues. The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.